Drug intelligence / Profile preview

VaxThera Zika vaccine

Development stage: Preclinical
Lead developer: VaxThera
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

VaxThera's Zika vaccine is a preclinical candidate being developed using both viral vector and mRNA platforms. The project is a collaborative effort between VaxThera, the University of Wisconsin, and the Universidad Nacional de Colombia, with co-funding from the Colombian Ministry of Science, Technology, and Innovation (Ministerio de Ciencia, Tecnología e Innovación de Colombia). The vaccine aims to induce protective immunity against the Zika virus by leveraging genetic delivery technologies to express viral antigens and stimulate neutralizing antibody and T-cell responses.

Other names: Zika vaccine (VaxThera)

Beyond the preview

Go deeper on VaxThera Zika vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VaxThera Zika vaccine.

Explore the full profile